# 2026-13616: FDA Quietly Retires 34 Forgotten Medicines

2026-13616, Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-07-06, effective 2026-08-05; PRIA reads it as touching household money (as of 2026-07-13).

- Canonical: https://policyrisk.com/federal-register/2026-13616
- As of: 2026-07-13
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-13616
- Title: Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 41045
- Published: 2026-07-06
- Effective: 2026-08-05
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-07-13

## In one line

FDA Quietly Retires 34 Forgotten Medicines

## Summary

The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.

## Abstract

The Food and Drug Administration (FDA or Agency) is withdrawing approval of 34 new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

## Effects PRIA read

- 34 Drug Approvals Withdrawn Aug 5, 2026: cost, medium. The FDA is withdrawing approval of 34 new drug applications (NDAs) as of August 5, 2026. After that date, introducing the listed products into interstate commerce would violate sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act.
- On‑hand Inventory Can Still Be Dispensed: benefit, low. Drug products listed in the withdrawal may continue to be dispensed from existing inventory until those inventories are depleted, the products reach their expiration dates, or they otherwise become violative. This temporary allowance applies starting August 5, 2026.
- Companies Waived Hearings; Can Refile: benefit, low. Applicants voluntarily requested withdrawal and waived their opportunity for a hearing; withdrawal under 21 CFR 314.150(c) is without prejudice to refiling, so companies may reapply for approval of these drugs in the future.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-13616 on federalregister.gov](https://www.federalregister.gov/documents/2026/07/06/2026-13616/endo-operations-limited-et-al-withdrawal-of-approval-of-34-new-drug-applications)
- [2026-13616 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-07-06/pdf/2026-13616.pdf)

## Related
- [Previous: 2026-13615, Draft Guidance for Reducing Risk From Perfluorooctanoic Acid (PFOA) and Perfluo…](https://policyrisk.com/federal-register/2026-13615)
- [Next: 2026-13617, New Postal Products](https://policyrisk.com/federal-register/2026-13617)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-13616 (as of 2026-07-13).
